These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 33837896)
1. Can breast MRI and adjunctive Doppler ultrasound improve the accuracy of predicting pathological complete response after neoadjuvant chemotherapy? Nakashima K; Uematsu T; Harada TL; Takahashi K; Nishimura S; Tadokoro Y; Hayashi T; Watanabe J; Sugino T; Notsu A Breast Cancer; 2021 Sep; 28(5):1120-1130. PubMed ID: 33837896 [TBL] [Abstract][Full Text] [Related]
2. Magnetic Resonance Imaging Combined With Second-look Ultrasonography in Predicting Pathologic Complete Response After Neoadjuvant Chemotherapy in Primary Breast Cancer Patients. Hayashi N; Tsunoda H; Namura M; Ochi T; Suzuki K; Yamauchi H; Nakamura S Clin Breast Cancer; 2019 Feb; 19(1):71-77. PubMed ID: 30206035 [TBL] [Abstract][Full Text] [Related]
3. Discrepancies Between Pathological Tumor Responses and Estimations of Complete Response by Magnetic Resonance Imaging After Neoadjuvant Chemotherapy Differ by Breast Cancer Subtype. Namura M; Tsunoda H; Yagata H; Hayashi N; Yoshida A; Morishita E; Takei J; Suzuki K; Yamauchi H Clin Breast Cancer; 2018 Apr; 18(2):128-134. PubMed ID: 28843513 [TBL] [Abstract][Full Text] [Related]
4. Prediction of pathologic complete response on MRI in patients with breast cancer receiving neoadjuvant chemotherapy according to molecular subtypes. Kim J; Han BK; Ko EY; Ko ES; Choi JS; Park KW Eur Radiol; 2022 Jun; 32(6):4056-4066. PubMed ID: 34989844 [TBL] [Abstract][Full Text] [Related]
5. Accuracy of digital mammography, ultrasound and MRI in predicting the pathological complete response and residual tumor size of breast cancer after completion of neoadjuvant chemotherapy. Sudhir R; Koppula VC; Rao TS; Sannapareddy K; Rajappa SJ; Murthy SS Indian J Cancer; 2022; 59(3):345-353. PubMed ID: 33753611 [TBL] [Abstract][Full Text] [Related]
6. Magnetic Resonance Imaging (MRI) Assessment of Residual Breast Cancer After Neoadjuvant Chemotherapy: Relevance to Tumor Subtypes and MRI Interpretation Threshold. Kim Y; Sim SH; Park B; Lee KS; Chae IH; Park IH; Kwon Y; Jung SY; Lee S; Ko K; Kang HS; Lee CW; Lee ES Clin Breast Cancer; 2018 Dec; 18(6):459-467.e1. PubMed ID: 29954674 [TBL] [Abstract][Full Text] [Related]
7. Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR). Gampenrieder SP; Peer A; Weismann C; Meissnitzer M; Rinnerthaler G; Webhofer J; Westphal T; Riedmann M; Meissnitzer T; Egger H; Klaassen Federspiel F; Reitsamer R; Hauser-Kronberger C; Stering K; Hergan K; Mlineritsch B; Greil R Breast Cancer Res; 2019 Jan; 21(1):19. PubMed ID: 30704493 [TBL] [Abstract][Full Text] [Related]
8. Prediction of pathologic complete response using image-guided biopsy after neoadjuvant chemotherapy in breast cancer patients selected based on MRI findings: a prospective feasibility trial. Lee HB; Han W; Kim SY; Cho N; Kim KE; Park JH; Ju YW; Lee ES; Lim SJ; Kim JH; Ryu HS; Lee DW; Kim M; Kim TY; Lee KH; Shin SU; Lee SH; Chang JM; Moon HG; Im SA; Moon WK; Park IA; Noh DY Breast Cancer Res Treat; 2020 Jul; 182(1):97-105. PubMed ID: 32418044 [TBL] [Abstract][Full Text] [Related]
9. Residual microcalcifications after neoadjuvant chemotherapy for locally advanced breast cancer: comparison of the accuracies of mammography and MRI in predicting pathological residual tumor. An YY; Kim SH; Kang BJ World J Surg Oncol; 2017 Nov; 15(1):198. PubMed ID: 29110671 [TBL] [Abstract][Full Text] [Related]
10. Ultrasound-based prediction of pathologic response to neoadjuvant chemotherapy in breast cancer patients. Baumgartner A; Tausch C; Hosch S; Papassotiropoulos B; Varga Z; Rageth C; Baege A Breast; 2018 Jun; 39():19-23. PubMed ID: 29518677 [TBL] [Abstract][Full Text] [Related]
11. Breast MRI for Evaluating Residual Tumor Size Following Neoadjuvant Chemotherapy: Clinicopathologic Factors and MRI Imaging Features Affecting its Accuracy. Park JY; Kim YS; Lee SE Curr Med Imaging; 2022; 18(8):876-882. PubMed ID: 34789137 [TBL] [Abstract][Full Text] [Related]
12. The Role of MRI in Assessing Residual Breast Cancer After Neoadjuvant Chemotherapy. Rezkallah E; Mekhaeil K; Tin SMM; Hanna RS Am Surg; 2024 Feb; 90(2):238-244. PubMed ID: 37611928 [TBL] [Abstract][Full Text] [Related]
13. Accuracy of Preoperative Contrast-enhanced Cone Beam Breast CT in Assessment of Residual Tumor after Neoadjuvant Chemotherapy: A Comparative Study with Breast MRI. Wang Y; Zhao M; Ma Y; Liu A; Zhu Y; Yin L; Liang Z; Qu Z; Lu H; Ma Y; Ye Z Acad Radiol; 2023 Sep; 30(9):1805-1815. PubMed ID: 36610931 [TBL] [Abstract][Full Text] [Related]
14. Multiparametric MR imaging to assess response following neoadjuvant systemic treatment in various breast cancer subtypes: Comparison between different definitions of pathologic complete response. Santamaría G; Bargalló X; Ganau S; Alonso I; Muñoz M; Mollà M; Fernández PL; Prat A Eur J Radiol; 2019 Aug; 117():132-139. PubMed ID: 31307638 [TBL] [Abstract][Full Text] [Related]
15. Prediction of pathological response to neoadjuvant chemotherapy in breast cancer patients by imaging. Kaise H; Shimizu F; Akazawa K; Hasegawa Y; Horiguchi J; Miura D; Kohno N; Ishikawa T J Surg Res; 2018 May; 225():175-180. PubMed ID: 29605029 [TBL] [Abstract][Full Text] [Related]
16. Comparing Accuracy of Mammography and Magnetic Resonance Imaging for Residual Calcified Lesions in Breast Cancer Patients Undergoing Neoadjuvant Systemic Therapy. Um E; Kang JW; Lee S; Kim HJ; Yoon TI; Sohn G; Chung IY; Kim J; Lee JW; Son BH; Ahn SH; Ko BS Clin Breast Cancer; 2018 Oct; 18(5):e1087-e1091. PubMed ID: 29703689 [TBL] [Abstract][Full Text] [Related]
17. Evaluating the role of magnetic resonance imaging post-neoadjuvant therapy for breast cancer in the NEONAB trial. Murphy C; Mukaro V; Tobler R; Asher R; Gibbs E; West L; Giuffre B; Baron-Hay S; Khasraw M Intern Med J; 2018 Jun; 48(6):699-705. PubMed ID: 28869790 [TBL] [Abstract][Full Text] [Related]
18. Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium trial 017. De Los Santos JF; Cantor A; Amos KD; Forero A; Golshan M; Horton JK; Hudis CA; Hylton NM; McGuire K; Meric-Bernstam F; Meszoely IM; Nanda R; Hwang ES Cancer; 2013 May; 119(10):1776-83. PubMed ID: 23436342 [TBL] [Abstract][Full Text] [Related]
19. Accuracy of Contrast-Enhanced Ultrasound Compared With Magnetic Resonance Imaging in Assessing the Tumor Response After Neoadjuvant Chemotherapy for Breast Cancer. Lee SC; Grant E; Sheth P; Garcia AA; Desai B; Ji L; Groshen S; Hwang D; Yamashita M; Hovanessian-Larsen L J Ultrasound Med; 2017 May; 36(5):901-911. PubMed ID: 28150325 [TBL] [Abstract][Full Text] [Related]
20. MRI evaluation of pathologically complete response and residual tumors in breast cancer after neoadjuvant chemotherapy. Chen JH; Feig B; Agrawal G; Yu H; Carpenter PM; Mehta RS; Nalcioglu O; Su MY Cancer; 2008 Jan; 112(1):17-26. PubMed ID: 18000804 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]